nach oben

Current Rheumatology Reports

Erschienen in:

01.10.2020 | Inflammatory Muscle Disease (L Diederichsen and H Chinoy, Section Editors)

Impact and Management of Dysphagia in Inflammatory Myopathies

verfasst von: Rachel Zeng, Jens Schmidt

Erschienen in: Current Rheumatology Reports | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Dysphagia is a common symptom in inflammatory myopathies. This review provides an overview on the epidemiology, clinical impact, and management of dysphagia in myositis. Relevant diagnostic tools and treatment strategies are discussed.

Recent Findings

Dysphagia can occur in any inflammatory myopathy, particularly in inclusion body myositis (IBM). It can lead to malnutrition or aspiration with subsequent pneumonia or even death. Dysphagia can be explored and monitored by patient-reported outcome scales for swallowing. New diagnostic tools such as real-time MRI and oro-pharyngo-esophageal scintigraphy have been studied for assessing dysphagia. Botulinum toxin injection can alleviate dysphagia in IBM. High-dose glucocorticosteroids are considered a first-line treatment for dysphagia in all other myositis subforms.

Summary

Evaluation of dysphagia in myositis requires thorough clinical workup and appropriate instrumental procedures. Treatment options are available for dysphagia, but controlled trials and consensus on best patient care are required for this important symptom.

Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5:109–29. https://doi.org/10.3233/JND-180308.CrossRefPubMedPubMedCentral

Ekberg O, Hamdy S, Woisard V, Wuttge-Hannig A, Ortega P. Social and psychological burden of dysphagia: its impact on diagnosis and treatment. Dysphagia. 2002;17:139–46. https://doi.org/10.1007/s00455-001-0113-5.CrossRefPubMed

• Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77:30–9. https://doi.org/10.1136/annrheumdis-2017-211868. This large multicenter cohort analysis included 3067 patients from 11 countries; associations between different myositis subtypes, extramuscular involvement, environmental exposure and medications were assessed.

Dobloug C, Garen T, Bitter H, Stjärne J, Stenseth G, Grøvle L, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis. 2015;74:1551–6. https://doi.org/10.1136/annrheumdis-2013-205127.

Marie I, Menard J-F, Hatron PY, Hachulla E, Mouthon L, Tiev K, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken). 2010;62:1748–55. https://doi.org/10.1002/acr.20325.CrossRef

Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Bassford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–7. https://doi.org/10.4065/82.4.441.CrossRefPubMed

Langdon PC, Mulcahy K, Shepherd KL, Low VH, Mastaglia FL. Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature. Dysphagia. 2012;27:408–17. https://doi.org/10.1007/s00455-011-9384-7.CrossRefPubMed

Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol. 2009;256:2009–13. https://doi.org/10.1007/s00415-009-5229-9.CrossRefPubMedPubMedCentral

Needham M, James I, Corbett A, Day T, Christiansen F, Phillips B, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry. 2008;79:1056–60. https://doi.org/10.1136/jnnp.2007.138891.

10.

Badrising UA, Maat-Schieman MLC, van Houwelingen JC, van Doorn PA, van Duinen SG, van Engelen BGM, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol. 2005;252:1448–54. https://doi.org/10.1007/s00415-005-0884-y.CrossRefPubMed

11.

Houser SM, Calabrese LH, Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope. 1998;108:1001–5. https://doi.org/10.1097/00005537-199807000-00009.CrossRefPubMed

12.

Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis: observations in 40 patients. Brain. 1989;112:727–47.CrossRef

13.

Casal-Dominguez M, Pinal-Fernandez I, Mego M, Accarino A, Jubany L, Azpiroz F, et al. High-resolution manometry in patients with idiopathic inflammatory myopathy: elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. Muscle Nerve. 2017;56:386–92. https://doi.org/10.1002/mus.25507.

14.

Mugii N, Hasegawa M, Matsushita T, Hamaguchi Y, Oohata S, Okita H, et al. Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS One. 2016;11:e0154746. https://doi.org/10.1371/journal.pone.0154746.

15.

Na S-J, Kim SM, Sunwoo IN, Choi Y-C. Clinical characteristics and outcomes of juvenile and adult dermatomyositis. J Korean Med Sci. 2009;24:715–21. https://doi.org/10.3346/jkms.2009.24.4.715.CrossRefPubMedPubMedCentral

16.

Parodi A, Caproni M, Marzano AV, de Simone C, La Placa M, Quaglino P, et al. Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol. 2002;82:48–51. https://doi.org/10.1080/000155502753600894.CrossRefPubMed

17.

Wintzen AR, Bots GT, de Bakker HM, Hulshof JH, Padberg GW. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51:1542–5. https://doi.org/10.1136/jnnp.51.12.1542.CrossRefPubMedPubMedCentral

18.

Riminton DS, Chambers ST, Parkin PJ, Pollock M, Donaldson IM. Inclusion body myositis presenting solely as dysphagia. Neurology. 1993;43:1241–3. https://doi.org/10.1212/WNL.43.6.1241.CrossRefPubMed

19.

Shapiro J, Martin S, DeGirolami U, Goyal R. Inflammatory myopathy causing pharyngeal dysphagia: a new entity. Ann Otol Rhinol Laryngol. 1996;105:331–5. https://doi.org/10.1177/000348949610500501.CrossRefPubMed

20.

Williams RB, Grehan MJ, Hersch M, Andre J, Cook IJ. Biomechanics, diagnosis, and treatment outcome in inflammatory myopathy presenting as oropharyngeal dysphagia. Gut. 2003;52:471–8. https://doi.org/10.1136/gut.52.4.471.CrossRefPubMedPubMedCentral

21.

Shibata S, Izumi R, Hara T, Ohshima R, Nakamura N, Suzuki N, et al. Five-year history of dysphagia as a sole initial symptom in inclusion body myositis. J Neurol Sci. 2017;381:325–7. https://doi.org/10.1016/j.jns.2017.09.014.

22.

Labeit B, Muhle P, Suntrup-Krueger S, Ahring S, Ruck T, Dziewas R, et al. Dysphagia as isolated manifestation of Jo-1 associated myositis? Front Neurol. 2019;10:739. https://doi.org/10.3389/fneur.2019.00739.

23.

Schrey A, Airas L, Jokela M, Pulkkinen J. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci. 2017;380:142–7. https://doi.org/10.1016/j.jns.2017.07.031.CrossRefPubMed

24.

Murata K-Y, Kouda K, Tajima F, Kondo T. A dysphagia study in patients with sporadic inclusion body myositis (s-IBM). Neurol Sci. 2012;33:765–70. https://doi.org/10.1007/s10072-011-0814-y.CrossRefPubMed

25.

Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83:35–42. https://doi.org/10.1097/01.md.0000109755.65914.5e.CrossRef

26.

Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum. 1985;28:249–55. https://doi.org/10.1002/art.1780280303.CrossRefPubMed

27.

Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14:275–85. https://doi.org/10.1007/s11926-012-0249-3.CrossRefPubMed

28.

Ponyi A, Constantin T, Garami M, András C, Tállai B, Váncsa A, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci. 2005;1051:64–71. https://doi.org/10.1196/annals.1361.047.CrossRefPubMed

29.

Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin. 2014;32:629–46, vii. https://doi.org/10.1016/j.ncl.2014.04.001.CrossRefPubMedPubMedCentral

30.

Lahouti AH, Amato AA, Christopher-Stine L. Inclusion body myositis: update. Curr Opin Rheumatol. 2014;26:690–6. https://doi.org/10.1097/BOR.0000000000000116.CrossRefPubMed

31.

Price MA, Barghout V, Benveniste O, Christopher-Stine L, Corbett A, de Visser M, et al. Mortality and causes of death in patients with sporadic inclusion body myositis: survey study based on the clinical experience of specialists in Australia, Europe and the USA. J Neuromuscul Dis. 2016;3:67–75. https://doi.org/10.3233/JND-150138.

32.

Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134:3176–84. https://doi.org/10.1093/brain/awr213.

33.

Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJGM, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167–75. https://doi.org/10.1093/brain/awr217.CrossRefPubMed

34.

• Taira K, Yamamoto T, Mori-Yoshimura M, Fujita S, Oya Y, Nishino I, et al. Obstruction-related dysphagia in inclusion body myositis: cricopharyngeal bar on videofluoroscopy indicates risk of aspiration. J Neurol Sci. 2020;413:116764. https://doi.org/10.1016/j.jns.2020.116764. This study analyzed the predictive risk factors for aspiration pneumonia in patients with inclusion body myositis; one of these factors was the presence of a cricopharyngeal bar (CB) on videofluoroscopic examination.

35.

Mulcahy KP, Langdon PC, Mastaglia F. Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence. Dysphagia. 2012;27:64–9. https://doi.org/10.1007/s00455-011-9338-0.CrossRefPubMed

36.

Wallace KL, Middleton S, Cook IJ. Development and validation of a self-report symptom inventory to assess the severity of oral-pharyngeal dysphagia. Gastroenterology. 2000;118:678–87.CrossRef

37.

Archer SK, Garrod R, Hart N, Miller S. Dysphagia in Duchenne muscular dystrophy assessed by validated questionnaire. Int J Lang Commun Disord. 2013;48:240–6. https://doi.org/10.1111/j.1460-6984.2012.00197.x.CrossRefPubMed

38.

McHorney CA, Robbins J, Lomax K, Rosenbek JC, Chignell K, Kramer AE, et al. The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia. 2002;17:97–114. https://doi.org/10.1007/s00455-001-0109-1.

39.

Olthoff A, Carstens P-O, Zhang S, von Fintel E, Friede T, Lotz J, et al. Evaluation of dysphagia by novel real-time MRI. Neurology. 2016;87:2132–8. https://doi.org/10.1212/WNL.0000000000003337.

40.

Patel DA, Sharda R, Hovis KL, Nichols EE, Sathe N, Penson DF, et al. Patient-reported outcome measures in dysphagia: a systematic review of instrument development and validation. Dis Esophagus. 2017;30:1–23. https://doi.org/10.1093/dote/dow028.

41.

Langmore SE. History of fiberoptic endoscopic evaluation of swallowing for evaluation and management of pharyngeal dysphagia: changes over the years. Dysphagia. 2017;32:27–38. https://doi.org/10.1007/s00455-016-9775-x.CrossRefPubMed

42.

Dziewas R, dem Brinke M a, Birkmann U, Bräuer G, Busch K, Cerra F, et al. Safety and clinical impact of FEES – results of the FEES-registry. Neurol Res Pract. 2019;1:2756. https://doi.org/10.1186/s42466-019-0021-5.CrossRef

43.

Audag N, Goubau C, Toussaint M, Reychler G. Screening and evaluation tools of dysphagia in adults with neuromuscular diseases: a systematic review. Ther Adv Chronic Dis. 2019;10:2040622318821622. https://doi.org/10.1177/2040622318821622.CrossRefPubMedPubMedCentral

44.

Cichero JAY, Murdoch BE. Dysphagia: foundation, theory and practice. Chichester, West Sussex PO19 8SQ, England: John Wiley & Sons, Ltd; 2006.

45.

Ryu JS, Park DH, Kang JY. Application and interpretation of high-resolution manometry for pharyngeal dysphagia. J Neurogastroenterol Motil. 2015;21:283–7. https://doi.org/10.5056/15009.CrossRefPubMedPubMedCentral

46.

Murata K-Y, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with dysphagia. Clin Med Insights Case Rep. 2013;6:1–7. https://doi.org/10.4137/CCRep.S10200.CrossRefPubMedPubMedCentral

47.

Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87:883–9. https://doi.org/10.1097/PHM.0b013e31818a50e2.CrossRefPubMed

48.

Lee YS, Lee KE, Kang Y, Im Yi T, Kim JS. Usefulness of submental ultrasonographic evaluation for dysphagia patients. Ann Rehabil Med. 2016;40:197–205. https://doi.org/10.5535/arm.2016.40.2.197.CrossRefPubMedPubMedCentral

49.

Miura Y, Nakagami G, Yabunaka K, Tohara H, Murayama R, Noguchi H, et al. Method for detection of aspiration based on B-mode video ultrasonography. Radiol Phys Technol. 2014;7:290–5. https://doi.org/10.1007/s12194-014-0264-3.

50.

Hsiao M-Y, Chang Y-C, Chen W-S, Chang H-Y, Wang T-G. Application of ultrasonography in assessing oropharyngeal dysphagia in stroke patients. Ultrasound Med Biol. 2012;38:1522–8. https://doi.org/10.1016/j.ultrasmedbio.2012.04.017.CrossRefPubMed

51.

Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–6. https://doi.org/10.1212/wnl.48.3.712.CrossRefPubMed

52.

Aydogdu I, Kiylioglu N, Tarlaci S, Tanriverdi Z, Alpaydin S, Acarer A, et al. Diagnostic value of “dysphagia limit” for neurogenic dysphagia: 17 years of experience in 1278 adults. Clin Neurophysiol. 2015;126:634–43. https://doi.org/10.1016/j.clinph.2014.06.035.

53.

Archer SK, Garrod R, Hart N, Miller S. Dysphagia in Duchenne muscular dystrophy assessed objectively by surface electromyography. Dysphagia. 2013;28:188–98. https://doi.org/10.1007/s00455-012-9429-6.CrossRefPubMed

54.

Ertekin C, Yüceyar N, Aydogdu I. Clinical and electrophysiological evaluation of dysphagia in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1998;65:848–56. https://doi.org/10.1136/jnnp.65.6.848.CrossRefPubMedPubMedCentral

55.

Barsotti S, Puccini G, Tripoli A, Cardelli C, Minichilli F, Volterrani D, et al. Assessment of swallowing function with oro-pharyngeal-esophageal scintigraphy in patients with idiopathic inflammatory myopathies. Neurogastroenterol Motil. 2019;31:e13599. https://doi.org/10.1111/nmo.13599.

56.

• Alexanderson H. Exercise in myositis. Curr Treatm Opt Rheumatol. 2018;4:289–98. https://doi.org/10.1007/s40674-018-0113-3. This review discusses the evidence for exercise as an important part of the treatment in patients with inflammatory myopathies.

57.

Johnson LG, Collier KE, Edwards DJ, Philippe DL, Eastwood PR, Walters SE, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10:178–84. https://doi.org/10.1097/CND.0b013e3181a23c86.

58.

Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med. 2003;35:31–5. https://doi.org/10.1080/16501970306110.CrossRefPubMed

59.

Malandraki GA, Kaufman A, Hind J, Ennis S, Gangnon R, Waclawik A, et al. The effects of lingual intervention in a patient with inclusion body myositis and Sjögren’s syndrome: a longitudinal case study. Arch Phys Med Rehabil. 2012;93:1469–75. https://doi.org/10.1016/j.apmr.2012.02.010.

60.

Mendelsohn MS, McConnel FM. Function in the pharyngoesophageal segment. Laryngoscope. 1987;97:483–9. https://doi.org/10.1288/00005537-198704000-00014.CrossRefPubMed

61.

Kahrilas PJ, Logemann JA, Krugler C, Flanagan E. Volitional augmentation of upper esophageal sphincter opening during swallowing. Am J Phys. 1991;260:G450–6. https://doi.org/10.1152/ajpgi.1991.260.3.G450.CrossRef

62.

Bodén K, Hallgren A, Witt HH. Effects of three different swallow maneuvers analyzed by videomanometry. Acta Radiol. 2006;47:628–33. https://doi.org/10.1080/02841850600774043.CrossRefPubMed

63.

• Beck AM, Kjaersgaard A, Hansen T, Poulsen I. Systematic review and evidence based recommendations on texture modified foods and thickened liquids for adults (above 17 years) with oropharyngeal dysphagia - an updated clinical guideline. Clin Nutr. 2018;37:1980–91. https://doi.org/10.1016/j.clnu.2017.09.002. This review discusses the evidence for the use of thickened liquids and modified food in patients with dysphagia; clinical recommendations are made.

64.

O’Keeffe ST. Use of modified diets to prevent aspiration in oropharyngeal dysphagia: is current practice justified? BMC Geriatr. 2018;18:167. https://doi.org/10.1186/s12877-018-0839-7.CrossRefPubMedPubMedCentral

65.

Ogawa-Momohara M, Muro Y, Kono M, Akiyama M. Prognosis of dysphagia in dermatomyositis. Clin Exp Rheumatol. 2019;165.

66.

Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2012;22:382–93. https://doi.org/10.1007/s10165-011-0534-4.CrossRefPubMed

67.

Marie I, Hachulla E, Levesque H, Reumont G, Ducrotte P, Cailleux N, et al. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol. 1999;26:2706–9.

68.

Vacchi C, Sebastiani M, Manfredi, A. and Ferri, C. A case of refractory dysphagia in the context of polymyositis treated with subcutaneous immunoglobulin and review of the literature. Clin Med Rev Case Rep 2017. doi:https://doi.org/10.23937/2378-3656/1410184.

69.

Cherin P, Delain J-C, Crave J-C, Cartry O. High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis. Case Rep Rheumatol. 2014;2014:458231–4. https://doi.org/10.1155/2014/458231.CrossRef

70.

Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58:326. https://doi.org/10.1212/wnl.58.2.326.

71.

Dobloug C, Walle-Hansen R, Gran JT, Molberg O. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol. 2012:838–42.

72.

Cherin P, Delain J-C, de Jaeger C, Crave J-C. Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases. Case Rep Neurol. 2015;7:227–32. https://doi.org/10.1159/000441490.CrossRefPubMedPubMedCentral

73.

Pars K, Garde N, Skripuletz T, Pul R, Dengler R, Stangel M. Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve. 2013;48:838–9. https://doi.org/10.1002/mus.23895.CrossRefPubMed

74.

Mohannak N, Pattison G, Hird K, Needham M. Dysphagia in patients with sporadic inclusion body myositis: management challenges. Int J Gen Med. 2019;12:465–74. https://doi.org/10.2147/IJGM.S198031.CrossRefPubMedPubMedCentral

75.

Dou Z, Zu Y, Wen H, Wan G, Jiang L, Hu Y. The effect of different catheter balloon dilatation modes on cricopharyngeal dysfunction in patients with dysphagia. Dysphagia. 2012;27:514–20. https://doi.org/10.1007/s00455-012-9402-4.CrossRefPubMed

76.

Parres C. Pharyngoesophageal dilation and botulinum toxin therapy for dysphagia in patients with inclusion body myositis (P3.157). Neurology. 2015:P3.157.

77.

Nagano H, Yoshifuku K, Kurono Y. Polymyositis with dysphagia treated with endoscopic balloon dilatation. Auris Nasus Larynx. 2009;36:705–8. https://doi.org/10.1016/j.anl.2009.04.007.CrossRefPubMed

78.

Schneider I, Thumfart WF, Pototschnig C, Eckel HE. Treatment of dysfunction of the cricopharyngeal muscle with botulinum a toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol. 1994;103:31–5. https://doi.org/10.1177/000348949410300105.CrossRefPubMed

79.

Alfonsi E, Merlo IM, Ponzio M, Montomoli C, Tassorelli C, Biancardi C, et al. An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment. J Neurol Neurosurg Psychiatry. 2010;81:54–60. https://doi.org/10.1136/jnnp.2009.174698.

80.

Krause E, Schirra J, Gürkov R. Botulinum toxin a treatment of cricopharyngeal dysphagia after subarachnoid hemorrhage. Dysphagia. 2008;23:406–10. https://doi.org/10.1007/s00455-007-9132-1.CrossRefPubMed

81.

Kim DY, C-i P, Ohn SH, Moon JY, Chang WH, S-w P. Botulinum toxin type A for poststroke cricopharyngeal muscle dysfunction. Arch Phys Med Rehabil. 2006;87:1346–51. https://doi.org/10.1016/j.apmr.2006.06.018.CrossRefPubMed

82.

Di Pede C, Masiero S, Bonsangue V, Ragona RM, Del Felice A. Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia. Neurol Sci. 2016;37:1743–5. https://doi.org/10.1007/s10072-016-2586-x.CrossRefPubMed

83.

Liu LWC, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol. 2004;18:397–9.CrossRef

84.

Haapaniemi JJ, Laurikainen EA, Pulkkinen J, Marttila RJ. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia. 2001;16:171–5. https://doi.org/10.1007/s00455-001-0059-7.CrossRefPubMed

85.

Kelly EA, Koszewski IJ, Jaradeh SS, Merati AL, Blumin JH, Bock JM. Botulinum toxin injection for the treatment of upper esophageal sphincter dysfunction. Ann Otol Rhinol Laryngol. 2013;122:100–8. https://doi.org/10.1177/000348941312200205.CrossRefPubMedPubMedCentral

86.

Shaw GY, Searl JP. Botulinum toxin treatment for cricopharyngeal dysfunction. Dysphagia. 2001;16:161–7. https://doi.org/10.1007/s00455-001-0074-8.CrossRefPubMed

87.

Danon MJ, Friedman M. Inclusion body myositis associated with progressive dysphagia: treatment with cricopharyngeal myotomy. Can J Neurol Sci. 1989;16:436–8. https://doi.org/10.1017/s031716710002953x.CrossRefPubMed

88.

Verma A, Bradley WG, Adesina AM, Sofferman R, Pendebury WW. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve. 1991;14:470–3.CrossRef

89.

Kagen LJ, Hochman RB, Strong EW. Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatomyositis). Report of three cases and review of the literature. Arthritis Rheum. 1985;28:630–6. https://doi.org/10.1002/art.1780280606.CrossRefPubMed

90.

Sanei-Moghaddam A, Kumar S, Jani P, Brierley C. Cricopharyngeal myotomy for cricopharyngeus stricture in an inclusion body myositis patient with hiatus hernia: a learning experience. BMJ Case Rep. 2013;2013:bcr2012008058. https://doi.org/10.1136/bcr-2012-008058.CrossRefPubMedPubMedCentral

91.

Williams RB, Ali GN, Hunt DR, Wallace KL, Cook IJ. Cricopharyngeal myotomy does not increase the risk of esophagopharyngeal acid regurgitation. Am J Gastroenterol. 1999;94:3448–54. https://doi.org/10.1111/j.1572-0241.1999.01507.x.CrossRefPubMed

92.

Kelly JH. Management of upper esophageal sphincter disorders: indications and complications of myotomy. Am J Med. 2000;108:43–6. https://doi.org/10.1016/s0002-9343(99)00334-4.CrossRef

93.

Rahnemai-Azar AA, Rahnemaiazar AA, Naghshizadian R, Kurtz A, Farkas DT. Percutaneous endoscopic gastrostomy: indications, technique, complications and management. World J Gastroenterol. 2014;20:7739–51. https://doi.org/10.3748/wjg.v20.i24.7739.CrossRefPubMedPubMedCentral

Titel: Impact and Management of Dysphagia in Inflammatory Myopathies
verfasst von: Rachel Zeng
Jens Schmidt
Publikationsdatum: 01.10.2020
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 10/2020
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-020-00950-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Impact and Management of Dysphagia in Inflammatory Myopathies

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Calcinosis in Systemic Sclerosis: Updates in Pathophysiology, Evaluation, and Treatment

Opioid Use and Total Joint Replacement

An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice

Complementary and Alternative Medicine Use in Rheumatoid Arthritis

The Many Faces of a Monogenic Autoinflammatory Disease: Adenosine Deaminase 2 Deficiency

Turning the Page in Osteoarthritis Assessment with the Use of Ultrasound

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin